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Abstract
b2-Glycoprotein I has a high affinity for triglyceride-rich particles, activates lipoprotein lipase,
and is also defined as an apolipoprotein H. Previous studies have shown that apolipoprotein H is a
regular structural component of the major classes of lipoproteins. In view of these findings, we
analyzed the interactions of apolipoprotein H with lipoproteins in the fasting plasma of eight
normal, seven hypertriglyceridemic, and seven hypercholesterolemic subjects. After rate-zonal,
density gradient ultracentrifugation, apolipoprotein H was little distributed among the different
density fractions, and most of it was recovered in the last fraction that contained the
lipoprotein-free plasma. A small percentage (4–13%) of the apolipoprotein H associated with
plasma lipoproteins was detected at the density ranging from 1.090 to 1.225 g/ml. This result
means that apolipoprotein H is little associated with lipoproteins. © 1999 Elsevier Science Inc. All
rights reserved.
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1. Introduction
b2-Glycoprotein I is a plasma glycoprotein that has a molecular weight ranging from
43 000 to 50 000 daltons [1,2]. It binds to platelet membranes; interacts with heparin;
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modulates the activity of adenylate cyclase; and because it inhibits the prothrombinase
activity on human platelets, may be involved in blood coagulation. Compared to other human
plasma proteins,b2-Glycoprotein I has a high content of cystein (6.2%) and proline (8.3%)
[1].
Becauseb2-Glycoprotein I is isolatable on plasma lipoprotein, has a high affinity for
triglyceride-rich lipoprotein particles, and activates lipoprotein lipase, it is also defined as an
apolipoprotein (apo)H [5]. ApoH shows a genetically determined structural polymorphism
caused by the presence of three common allelic forms at a single structural locus that
determine six different phenotypes [6,7]. In our previous work, we found an association
between hyper-triglyceridemia and apoH polymorphism, especially with the H*3 allele [8].
Although its physical and chemical characteristics are well studied, its physiological
functions remain unknown. ApoH also displays anticoagulant properties, and interference
with its function by anti-phospholipid antibodies could explain the thrombotic diathesis seen
in association with these antibodies: apoH is the target to which antibodies are directed
[9–11].
According to Polz and Kostner [12], apoH is a regular structural component of chylomi-
crons, very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-
density lipoproteins (HDL). It has been reported that apoH has a high affinity for triglyceride-
rich particles, causing their selective precipitation by detergents such as sodium lauryl sulfate
or sodium dodecyl sulfate [13], and activates lipoprotein lipase in the in vitro hydrolysis of
artificial lipid emulsions [14]. In view of these findings, we analyzed the interactions of apoH
with lipoproteins in fasting plasma of eight normal subjects, seven hypertriglyceridemic
subjects, and seven hypercholesterolemic subjects.
2. Materials and Methods
2.1. Materials
Tris, urea, Tween 20, acrylamide, and N,N’-methylene-bis-acrylamide, analytical grade,
were purchased from Bio-Rad (Richmond, CA, USA). Nitrocellulose sheets were also from
Bio-Rad. Rabbit polyclonal antibody to apoH was kindly supplied by Behring (Scoppito,
Italy). Goat anti-rabbit IgG (alkaline phosphatase conjugated), the alkaline phosphatase
conjugate substrate kit, molecular weight standards were from Bio-Rad, and Prep-Cell was
bought from Bio-Rad. Centricon tubes were from Amicon (Beverly, MA, USA). The
cyanogen bromide activated Sepharose 6B column was purchased from Pharmacia Biotech
(Uppsala, Sweden)
2.2. Subjects
We investigated the binding of apoH to plasma lipoproteins. We enrolled seven hyper-
triglyceridemic subjects (three males and four females, age range 32–60 years, triglycerides
level .250 mg/dl), seven hypercholesterolemic subjects (three males and four females, age
range 27–58 years, total cholesterol.240 mg/dl), and eight normal subjects (four males and
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four females, age range 30–55 years). Plasma samples and the ultracentrifugation fractions
were assayed for their content of apoH with an enzyme-linked immunosorbent assay
(ELISA) method.
2.3. Separation of lipoproteins
After 12 h of fasting, blood was drawn from each subject and placed in a vacutainer tube
containing K3 ethylene-diaminetetraacetic acid (EDTA) as an anticoagulant. Plasma was
obtained by low speed centrifugation at 30003 g at 4°C for 15 min and, lipoproteins were
separated by preparative ultracentrifugation. Plasma was adjusted to the density of 1.220
g/ml by adding solid KBr (0.352 g/ml) and brought to a final volume of 2 ml with a salt
solution of the same density. The samples were sealed in Quick-Seal tubes and ultracentri-
fuged at 60 0003 g for 48 h at 12°C in a TL-100 ultracentrifuge (Beckman Instruments Inc.,
Palo Alto, CA, USA). The floating lipoproteins were removed by tube slicing.
To confirm the poor binding of apoH to lipoproteins, plasma from one subject from each
group was subjected to a density gradient ultracentrifugation [15]. The rate-zonal, density
gradient ultracentrifugation used was originally developed for the separation of the high
density lipoprotein subclasses HDL2 and HDL3 from human plasma. (VLDL and LDL were
not separated from each other by this procedure.) This method of separation is based on the
difference in the floation rate of the high density lipoprotein subclasses. The density profile
of a NaBr gradient after ultracentrifugation is displayed in Fig. 1. The gradient fractions were
analyzed for cholesterol, triglycerides, and the distribution of apoH.
Plasma was adjusted to a density of 1.40 g/ml by adding solid KBr. Aliquots (2-ml) were
pipetted on the bottom of Beckman Ultra-Clear SW-40 tubes and over-layered with 2.5 ml
NaBr-1 mM EDTA (pH 7.4), density 1.25 g/ml; 7.5 ml NaBr-1 mM EDTA (pH 7.4), density
1.19 g/ml; and 2.0 ml 1 mM EDTA (pH 7.4). The gradients were centrifuged at 15°C for 21 h
Fig. 1. Density profile of NaBr gradient after ultracentrifugation. The x axis represents the number of the fractions
collected from the gradient. The y axis represents the density of each fraction. The bottom of the sample is on
the right, and the top is on the left. The gradient was centrifuged and fractionated as indicated in Methods and
materials.
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at 40 0003 g in a Ti SW-40 swinging bucket rotor using a Beckman LM-70 ultracentrifuge.
After the run, the tubes were punctured from the bottom, and 0.75 ml fractions were collected
(Density Gradient Fractionator, Model 185, ISCO Inc., Lincoln, NE, USA). Absorbance was
measured at 254 nm. Fractions were assayed for cholesterol and triglycerides content.
2.4. Dot blot analysis
Rapid screening of the fractions for apoH content after density gradient ultracentrifugation
was conducted in a Bio-Dot micro-filtration apparatus (Bio-Rad). A sheet of nitrocellulose
was clamped between a gasket and a 96-well sample template. Sample (5ml) was allowed
to filter through the membrane. After the antigen was immobilized, the nitrocellulose was
incubated in 4% albumin-blocking solution. The nitrocellulose was subsequently incubated
with rabbit IgG anti-apoH, at a 1:2000 dilution at room temperature for 1.5 h, and then with
goat IgG anti-rabbit IgG labeled with alkaline phosphatase at a 1:6000 dilution (Sigma,
Milan, Italy). Dots were visualized with Immun-Blot Assay kit (Bio-Rad) by following the
manufacturer’s instructions.
2.5. Isolation and purification of apoH
ApoH was isolated from human plasma and purified through a combination of affinity
chromatography and continuous-elution electrophoresis as previously described [16].
Briefly, rabbit anti-human apoH antibodies were immobilized on a cyanogen-bromide
activated Sepharose 6B column (Pharmacia Biotech), and normal plasma samples were
applied. The apoH bound to the column was eluted with 0.1 M glycine, 0.05% NaN3, pH 2.5,
and concentrated to a final volume of;1 ml. To achieve maximum purification of the apoH,
the concentrated sample was then subjected to continuous-elution electrophoresis in a
Prep-Cell (Bio-Rad) at 40 mA through a cylindrical gel made with 8.5% polyacrylamide. The
samples containing apoH were subjected to 12% sodium dodecyl sulfate polyacrilamide gel
electrophoresis and immunoblotted after to a nitrocellulose sheet electrophoretic transfer.
The purified apolipoprotein migrated as a single band on the sodium dodecyl sulfate gel
electrophoresis and reacted with the specific antibody. The amino acid analysis of our
purified apoH was similar to that reported by Steinkasserer et al. [17]. ApoH, in its pure form,
was used for both horse-radish-peroxidase (HRP) labeling and as the standard for the ELISA.
The Bio–Rad protein assay was used to measure the purified apoH concentration. An
Ouchterlony plate analysis against purified apoH, apoE, albumin, transferrin,a-1 acid
glycoprotein, andb2-microglobulin showed only one precipitating arc between anti-apoH
and purified apoH.
2.6. ELISA method
ELISA was performed as previously described [18] with some modifications. The two-
step glutaraldehyde method was used. Briefly, glutaraldehyde was diluted in 0.1 M phos-
phate buffer, pH 6.8, to a final concentration of 1.25%. HRP (5 mg) was dissolved in 0.1 ml
glutaraldehyde solution and allowed to incubate overnight at room temperature. The HRP-
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glutaraldehyde mix was added to an apoH solution (400mg in 200 ml 0.1 M carbonate/
bicarbonate buffer, pH 9.5) and incubated overnight at room temperature. The remaining
sites were blocked with 0.2 M ethanolamine, pH 7, for 2 h at 4°C.Labeled apoH was
dialyzed in 0.05 M Tris 0.15 M NaCl, pH 7.4, overnight at 4°C. The unconjugated HRP
molecules were removed by gel filtration.
Rabbit anti-apoH antibodies were diluted 1:8000 with 0.05 M carbonate/bicarbonate
buffer, pH 9.5, and 100ml were pipetted into each well of a 96-well microtiter plate. This
was then sealed and left at 37°C for 1 h. Washing with 0.02 M sodium phosphate, pH 7.8,
0.15 M NaCl (phosphate-buffered saline) to remove unbound antibodies was followed by a
blockade of the remaining sites by incubation with 350ml 4% bovine serum albumin in
phosphate-buffered saline for 1 h at37°C.
Unknown plasma samples and standards were diluted in assay buffer solution before being
assayed. The optimum ELISA conditions were 50ml standards or plasma diluted 400-fold
and 50ml purified apoH labeled with HRP diluted 1000-fold. Samples were pipetted into the
wells of pre-coated microtiter plate, which was then covered and incubated for 2 1/2 h at
37°C.
The plate was washed six times with assay buffer solution. A freshly prepared enzyme
substrate solution (100ml), made by dissolving an o-phenylendiamine dihydrochloride tablet
in 0.05 M phosphate-citrated buffer, pH 5.0 to a final concentration of 1 mg/ml was added
to the wells. The plate was briefly agitated, covered, and left in the dark at room temperature
for 20 min. The reaction was then stopped by adding 50ml 3M HCl to each well, and the
plate was agitated to ensure thorough mixing. Well absorbance was measured with a Bio-Rad
3550 reader at 490 nm. Plasma concentrations were expressed in mg/dl. The standard curves
were constructed with apoH isolated from human plasma. The working range was from 1.9
to 120 mg/dl.
The intra-assay coefficient of variation (CV) for each sample calculated from the results
of 10 pairs of wells in a single assay was 3.8–5.0%. The inter-assay CV for each sample
calculated from the results of pairs of wells in five assays was 6.2–8.8%. In the absence of
appropriate apoH reference plasma, accuracy was determined from the recovery that was
obtained after the addition of our isolated apoH in known concentrations to normal plasma.
3. Results
Total plasma levels of triglycerides, cholesterol, and apoH in normal, hypercholestero-
lemic, and hypertriglyceridemic subjects who were recruited in accordance with the reported
parameters are described in Table 1. This table also reports the percentage of apoH bound to
the lipoproteins that were separated by preparative ultracentrifugation, expressed as the top
and bottom of samples that were raised at 1.220 g/ml density. Our results show that apoH is
little bound to the fraction containing the lipoproteins (Table 1).
After the rate-zonal, density gradient ultracentrifugation, the gradient fractions were
analyzed for cholesterol, triglycerides, and the distribution of apoH. The cholesterol and
triglyceride concentrations were in accordance with the chemical composition of plasma
lipoproteins. As for the apoH, most of it (dot blot of plasma from one subject from each
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group) was recovered in the last fractions that contained the lipoprotein-free plasma (Fig. 2).
A small percentage of the apoH associated with plasma lipoproteins was detected at density
ranging from 1.090 to 1.220 g/ml. This result means that apoH was predominantly found in
the fractions that had a density above 1.230 g/ml.
Table 1
Total plasma levels of triglycerides, cholesterol, and apoH in normal (n 5 8), hypercholesterolemic (n 5












Normals (n 5 8) 1286 56 1896 26 136 4.4 3.6 96.4
Hyper-Tg (n 5 7) 3576 61 1996 34 426 13 10.4 89.6
Hyper-Chol (n 5 7) 1476 45 2816 18 296 10 13.2 84.9
Reported are the percentage of apoH bound to the lipoproteins separated by preparative ultracentrifugation and
expressed as top and bottom of samples raised at 1.220 g/ml density. Values are mean6 SD.
Fig. 2. Dot blot of the fractions collected from the gradient after rate-zonal ultracentrifugation of the plasma from
one subject from each group. Dots A–B refer to one hypercholesterolemic subject; dots C–D refer to one
hypertriglyceridemic subject; dots E–F refer to normal subject. Dots A1–3, C1–3, E1–3 show the presence of
apoH in VLDL and LDL. Dots A4–10, C4–10, E4–10 show the presence of apoH in HDL2 and HDL3. Dots
B1–10, D1–10, F1–9 shows the presence of apoH in the lipoprotein-free plasma. Dot-blotting analysis shows that
most of apoH is lipoprotein-free as indicated by the positive dots B5–6–7, D4–5–6, and F6.
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4. Discussion
Becauseb2-Glycoprotein I is isolatable on plasma lipoprotein, has a high affinity for
triglyceride-rich lipoprotein particles, and activates lipoprotein lipase, it is also defined as
apoH [5]. ApoH has been identified as a component of circulating plasma lipoproteins [2,5].
Despite being a component of plasma, this apolipoprotein displays behavior that is substan-
tially different from other apolipoproteins that form the integral components of plasma
lipoproteins [19]. Whereas the conformation of these apolipoproteins changes in the presence
of lipid, the secondary and tertiary organization of apoH, at neutral pH, may be similar in the
lipidated and lipid-free states [5]. Moreover, apoH associates with plasma lipoproteins
through protein-protein interactions rather than protein-lipid interactions, and the secondary
structure of apoH is different from other apolipoproteins [5].
Chylomicrons and VLDL, secreted by the intestine and liver, respectively, are large
lipid-protein complexes that are involved in the transport and metabolism of triglycerides,
cholesterol, and cholesterol esters. The nascent particles, which are composed primarily of
apolipoprotein B and lipids, gain additional apolipoproteins on entering the plasma [20,21].
Polz and Kostner [12] found apoH in chylomicrons, VLDL, LDL and HDL. Approximately
16% by weight of plasma apoH was found with chylomicron and VLDL, 2% with LDL, 17%
with HDL, and the remainder (65%) in the 1.21 g/ml density infranatant.
In this work, we performed a similar experiment and plasma apoH levels were quantified
with a competitive ELISA method [18]. Sensitivity and specificity of the method was
satisfactory, and the performance of subsequent assays was not affected by the inter-assay
CV. Cassader et al. [18] reported the mean value obtained in a normal population (22.56
7.7 mg/dl) was similar to that observed, in a smaller study using a (RIA) method [22] and
to that observed in a study comparing Laurell rocket immunoelectrophoresis with the ELISA
technique [23]. This method was chosen to rule out the possibility of interference by proteins
possessing some degree of affinity with the polyclonal antibody employed. Interference of
various kinds, in fact, as well as technical problems, were encountered when a sandwich
ELISA was used to measure urinary apoH levels [24].
After the removal of all lipoproteins from the plasma at a density of 1.230 g/ml, the largest
amount of apoH was found in the bottom fraction. Just a small percentage of apoH was
associated with lipoproteins. Our results differ from those reported by [12]. The percentage
of lipoprotein-bound apoH they found was higher than the percentage we found.
The rate-zonal, density gradient ultracentrifugation used was originally developed for the
separation of the high density lipoprotein subclasses HDL2 and HDL3 from human serum.
(VLDL and LDL were not separated from each other by this procedure.) This method of
separation is based on the difference in the flotation rate of the high density lipoprotein
subclasses. The gradient fractions were analyzed for cholesterol, triglycerides, and the
distribution of apoH. The cholesterol and triglyceride profiles were in accordance with the
chemical composition of plasma lipoproteins.
Most of the apoH was recovered in the last fractions that contained the lipoprotein-free
plasma. Small percentages (4–13%) of the apoH associated with plasma lipoproteins were
detected. This result means that apoH is predominantly found in the fractions with a density
above 1.230 g/ml. This observations agrees with the work of Polz and Kostner [12], who
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found most of the apoH in the bottom fraction, too, but conflicts with their results in the
percentages of free and lipoprotein-associated apoH. We report here that.95% of the apoH
was not associated with lipoproteins in normal subjects and that apoH becomes more
associated with lipoproteins in hypertriglyceridemic and hypercholesterolemic subjects. This
increase of associated apoH could reflects a higher production of VLDL and LDL. This
discrepancy could be due to an overestimation of the apoH in lipoproteins classes probably
from a cross-reaction of the antibody used in the radial immunodiffusion. As a matter of fact,
apoH belongs to a wide family of proteins that share a common repeat unit [25].
Our result is in agreement with our previous report [8] where we found only traces of
apoH bound to plasma lipoproteins. Moreover, the sample collected from the affinity column
contained apoH and other contaminating proteins. No lipoproteins were found in the eluate.
One can assume that the apoH is masked on the lipoprotein surface and not recognized by
the antibody. But the apolipoproteins were located on the outer surface of a lipoprotein and
should be accessible to antibody. This observation led us to study the distribution of apoH
in the major classes of lipoproteins after removal of lipoproteins from plasma through
ultracentrifugation. Isolation of lipoproteins did not affect the binding of apoH to lipopro-
teins because the protein sediments slowly during ultracentrifugation, and any loss of protein
from lipoproteins should be excluded [12]. This was supported by the fact that no classes of
plasma lipoproteins could be isolated by affinity chromatography through an anti-apoH
column as described above.
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